We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US-based drug delivery technology company Catalent has agreed to purchase all outstanding shares of specialty healthcare firm Juniper Pharmaceuticals for a total cash consideration of $139.6m, which represents $11.50 per share.